Pzena Investment Management Trims Major Stakes in UBS, Adient, and Univest in Q1

UBS stock opened at $49.76 on Thursday, providing market context as Pzena reduced its UBS stake to 26,544,355 shares (after selling 3,230,218 in Q1).
In Adient, EVP Heather M. Tiltmann sold 22,000 shares in a June 4 filing at an average price of $22.71, reducing her ownership by 16.56% to 110,886 shares (about $2.52 million).
Other major investors adjusted UBS positions in Q1: AQR Capital Management up 73.9% to 62,912 shares; MIRAE Asset Global ETFs up 18.6% to 4,518 shares; NewEdge Advisors up 3.1% to 41,772 shares; Focus Partners Wealth up 11.6% to 14,111 shares; and Geneos Wealth Management up 62.0% to 1,497 shares.
UBS-wide developments in the week included Erste Group Bank raising UBS earnings estimates for FY2026 to $3.43 and FY2027 to $4.10, UBS Global Wealth Report 2026 highlighting a surge in wealth (nearly one million new millionaires in 2025), and UBS updating its U.S. tax counsel opinion for a debt securities shelf.
For Univest, hedge funds and other institutional investors own about 75.07% of UVSP; Geneos Wealth Management increased its UVSP stake by 545.3% in Q1 to 2,665 shares; Weiss Ratings reissued a buy rating on UVSP.
Pzena Investment Management trimmed its UBS Group AG stake by 10.8% in the first quarter of 2026, selling 3,230,218 shares and leaving the firm with 26,544,355 shares worth about $1.04 billion, according to MarketBeat. The reduction makes UBS roughly 3.4% of Pzena's total holdings, ranking it as the firm's fifth-largest position.
The move reflects a pattern of selective trimming rather than a broad retreat. Pzena also cut its Adient stake by 1.1% and its Univest Corporation holding by 1.6% during the same period — while other institutions were actively buying UBS shares.
Pzena sold down its Adient plc position to 3,635,297 shares, worth roughly $73.5 million. Its Univest Corporation of Pennsylvania stake fell to 842,425 shares, valued at about $28.9 million, per Stockzoa. Neither cut was dramatic — both were under 2% — suggesting mechanical rebalancing rather than a loss of conviction.
Pzena is a self-described "deep value" manager. Its strategy is to buy unloved stocks cheap and sell as they approach fair value. The UBS trim fits that playbook: UBS stock opened at $49.76 on Thursday, July 2, reflecting a strong run since Pzena first built its position.
Not everyone was trimming. AQR Capital Management increased its UBS stake by 73.9% in Q1, ending with 62,912 shares. Geneos Wealth Management jumped 62.0% to 1,497 shares. MIRAE Asset Global ETFs added 18.6% to reach 4,518 shares, according to MarketBeat. These quantitative and ETF-driven buyers appear to be chasing UBS's earnings momentum.
That momentum is real. UBS posted Q1 2026 earnings per share of $0.94, beating the $0.85 consensus. Erste Group Bank analyst S. Lingnau raised FY2026 earnings estimates to $3.43 and FY2027 estimates to $4.10, citing the bank's growing earnings power as its Credit Suisse integration nears completion, per MarketBeat.
Alongside Pzena's Adient trim, the company's own Executive Vice President Heather M. Tiltmann sold 22,000 shares on June 4 at an average price of $22.71 per share, per Stock Titan. That cut her personal ownership by 16.56%, leaving her with 110,886 shares worth about $2.52 million.
Insider sales are not always a red flag, but they draw attention in a volatile sector. Adient supplies seating systems to automakers, an industry facing ongoing pressure from slowing vehicle demand. Both Pzena's institutional trim and Tiltmann's personal sale point to caution around the stock's near-term outlook.
UBS released its Global Wealth Report 2026 on June 30, showing global personal wealth grew 10.8% in 2025 — the fastest rate in at least three years. The U.S. alone added over 440,000 new millionaires last year, roughly 1,200 per day, according to Quartz.
That wealth surge directly fuels UBS's core wealth management business. The bank has also updated its U.S. tax counsel opinion for a debt securities shelf, signaling readiness for future capital market activity. Weiss Ratings separately reissued a buy rating on Univest, even as Pzena nudged its stake lower — a reminder that one seller does not make a trend.
Publishers
34
Articles
25
Reach
59